A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy

任天堂 医学 安慰剂 内科学 放射治疗 不良事件通用术语标准 特发性肺纤维化 临床终点 胃肠病学 肿瘤科 随机对照试验 不利影响 肺炎 外科 病理 替代医学
作者
Grace K. Dy,Dheerendra Prasad,Prasanna Kumar,Kristopher Attwood,Alex A. Adjei
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:16 (3): e19-e20 被引量:13
标识
DOI:10.1016/j.jtho.2020.11.019
摘要

Nintedanib is a multikinase inhibitor that is U.S. Food and Drug Administration–approved for the treatment of interstitial lung disease.1Richeldi L. Costabel U. Selman M. et al.Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.N Engl J Med. 2011; 365: 1079-1087Crossref PubMed Scopus (768) Google Scholar,2Richeldi L. Du Bois R. Raghu G. et al.Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med. 2014; 370 (2701–2082)Crossref Scopus (2334) Google Scholar We report the results of the first randomized, placebo-controlled, double-blind trial conducted to determine whether nintedanib will reduce the rate of symptomatic radiation pneumonitis in patients with unresectable NSCLC after completion of concurrent chemoradiation therapy. Patients with unresectable stage II/III NSCLC who received concurrent chemoradiation (54–66 Gy thoracic radiation dose) and with at least stable disease after completing the last fraction of radiation treatment were randomized in 2:1 fashion to start nintedanib 200 mg or placebo twice daily no later than 6 weeks after completing the last dose of radiation. Nintedanib or placebo was administered for 6 months. The primary end point was the rate of symptomatic Common Terminology Criteria for Adverse Events grade 2 or higher radiation pneumonitis after completion of chemoradiation. The secondary end points were to compare survival and pulmonary function. A maximum of 99 participants, stratified by chemotherapy regimen, was planned with 81% probability of detecting a clinically significant reduction in the expected rate of grade 2 or higher radiation pneumonitis from 30% to 10%, at an α significance level of 0.05. A total of eight patients (nintedanib, n = 5; placebo, n = 3) underwent randomization before the trial was closed in June 2019 owing to poor accrual and change in the standard of care with the approval of durvalumab.3Antonia S.J. Villegas A. Daniel D. et al.Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.N Engl J Med. 2018; 379: 2342-2350Crossref PubMed Scopus (1266) Google Scholar One treatment-related Common Terminology Criteria for Adverse Events grade 5 hemorrhagic fatality occurred in a nintedanib-assigned patient with squamous cell histology. The protocol was subsequently amended to only enroll patients with nonsquamous histology. None of the five nintedanib-assigned patients encountered the event of interest whereas 67% (two of three) of placebo-assigned patients had clinically significant pneumonitis deemed to be related to radiation, requiring oxygen supplementation and steroid treatment. These two placebo-treated patients received higher V5 (percent of lung volume receiving ≥5 Gy) dose to contralateral lung (63 Gy and 72 Gy, respectively) compared with the remaining placebo- or nintedanib-treated patients who did not develop symptomatic pneumonitis attributed to radiation (range = 7–25 Gy). No clinically significant differences were found otherwise with baseline demographics and other dosimetric parameters between groups (V20 [percent of lung volume receiving ≥20 Gy], mean lung dose, gross tumor volume dose). Furthermore, there were no clinically relevant differences observed in pulmonary function, progression-free survival, nor overall survival between the groups. In summary, there were more clinically significant symptomatic radiation pneumonitis events that occurred in the patients assigned to placebo versus the nintedanib group. However, because the study was terminated prematurely owing to accrual logistics and there were potential treatment imbalances in this small sample size, our study is unable to conclusively prove or disprove the role of nintedanib in mitigating radiation pneumonitis. Our study illustrates the accrual challenges posed by standard-of-care changes during the enrollment period. Nonetheless, the preliminary efficacy and safety data will provide important context in the future in the interpretation of the yet-to-be reported results of the ongoing double-blind, randomized, placebo-controlled trial evaluating the addition of nintedanib to prednisone in patients with acute radiation pneumonitis in reducing acute pulmonary exacerbations as primary outcome (NCT02496585). This study was approved and funded by the National Comprehensive Cancer Network Oncology Research Program from the general research support provided by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI had no role in the design, analysis, or interpretation of the results in this study; BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BIPI substances and intellectual property considerations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
念姬发布了新的文献求助10
1秒前
CatC完成签到,获得积分10
1秒前
英俊的汉堡完成签到,获得积分10
2秒前
lucky完成签到,获得积分10
3秒前
5秒前
6秒前
bkagyin应助鱼咬羊采纳,获得10
6秒前
Leeny发布了新的文献求助10
7秒前
8秒前
8秒前
飞行中的鱼完成签到,获得积分20
9秒前
牛牛眉目发布了新的文献求助10
10秒前
菲晗子完成签到,获得积分20
10秒前
茜茜哎科研应助湛湛采纳,获得10
10秒前
zx发布了新的文献求助10
12秒前
13秒前
14秒前
土豪的雪巧完成签到,获得积分10
15秒前
雨的前世完成签到,获得积分10
18秒前
18秒前
Sun发布了新的文献求助10
19秒前
gulllluuuukk完成签到,获得积分10
19秒前
可可西里完成签到,获得积分10
19秒前
20秒前
茜茜哎科研应助傅勃霖采纳,获得10
20秒前
20秒前
Lee发布了新的文献求助10
21秒前
22秒前
22秒前
牛牛眉目发布了新的文献求助10
23秒前
yang发布了新的文献求助10
25秒前
蛋挞完成签到 ,获得积分10
26秒前
李爱国应助zx采纳,获得10
26秒前
bunny完成签到,获得积分20
27秒前
新威宝贝完成签到,获得积分10
29秒前
29秒前
xr完成签到 ,获得积分10
29秒前
张雷应助yangyl采纳,获得10
30秒前
AXEDW完成签到 ,获得积分10
32秒前
csy完成签到,获得积分10
35秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3966366
求助须知:如何正确求助?哪些是违规求助? 3511778
关于积分的说明 11159852
捐赠科研通 3246372
什么是DOI,文献DOI怎么找? 1793416
邀请新用户注册赠送积分活动 874427
科研通“疑难数据库(出版商)”最低求助积分说明 804388